Next-Generation Cell-Penetrating Peptides: Smarter Drug Delivery That Can Cross Skin, Brain, and Eye Barriers

This is a narrative review of recent literature on next-generation cell-penetrating peptides. It covers CPPs derived from natural sources (venoms, bacterial proteins, cathelicidins) as well as rationally designed hybrid structures. The review discusses mechanisms of cell entry, nanoparticle conjugation strategies, barrier-crossing capabilities, and 3D tissue penetration for tumor treatment.

Getting drugs to the right cells inside the body remains one of medicine's biggest challenges. Most large therapeutic molecules (proteins, nucleic acids, antibodies) cannot cross cell membranes on their own. CPPs that can selectively deliver these cargoes to tumor cells, across the blood-brain barrier, or through skin could transform treatment for cancer, neurological diseases, and eye conditions — while making treatment less invasive and more patient-friendly.

Cell-penetrating peptides represent a convergence of peptide science, nanotechnology, and drug delivery engineering. As biologics (proteins, antibodies, gene therapies) become an ever-larger share of the drug pipeline, the need for efficient intracellular delivery systems grows. New-generation CPPs that can target specific tissues and cross biological barriers could enable therapies that are currently impossible — particularly for brain diseases where the blood-brain barrier blocks most drugs.

This is a review article that does not generate new experimental data. Most CPPs discussed remain in preclinical development. Comparing CPP efficacy is inherently difficult because performance depends on the specific cargo, target tissue, coupling method, and experimental conditions. Clinical translation faces challenges including manufacturing scalability, immunogenicity, and regulatory approval of novel delivery systems.